Efficacy and tolerability of micafungin monotherapy for candidemia and deep-seated candidiasis in adults with cancer

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

The response rate among 58 patients with cancer and candidemia or deep-seated candidiasis treated with micafungin monotherapy was 81%. Intensive care unit (ICU) stay, concomitant nonfungal infections, and acute kidney injury were significantly associated with the 30-day crude mortality rate. Severe neutropenia was an independent predictor of micafungin failure. The efficacy and safety of micafungin in cancer patients with invasive candidiasis were comparable to those reported for patients without malignancy and for cancer patients treated with caspofungin.

Original languageEnglish (US)
Pages (from-to)3526-3529
Number of pages4
JournalAntimicrobial agents and chemotherapy
Volume58
Issue number6
DOIs
StatePublished - Jun 2014

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Efficacy and tolerability of micafungin monotherapy for candidemia and deep-seated candidiasis in adults with cancer'. Together they form a unique fingerprint.

Cite this